Pharmacologic treatments for covid-19 patients

Lopinavir + Ritonavir vs Standard care


Outpatients

Forest plots
(last update: 2022-04-15)

Summary of findings
(last update: 2022-09-16)

Hospitalized patients

Forest plots
(last update: 2022-04-29)

Summary of findings
(last update: 2022-09-23)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=1

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04499677
FLARE
Lowe DM, medRxiv, 2022
Full text
Commentary
Commentary
Mixed

Favipiravir

Lopinavir-Ritonavir

LPV/r+FAV

Favipiravir

Placebo

Placebo

Placebo

Lopinavir-Ritonavir

RCT Outpatients with confirmed COVID-19 (asymptomatic-mild) treated by 2 centers in the UK N=240
Some concerns
Details

Full description

NCT02735707
Arabi Y, Intensive Care Med, 2021
Full text
Commentary
Mixed

Lopinavir-Ritonavir

Hydroxychloroquine

HCQ+LPV/r

Lopinavir-Ritonavir

Lopinavir-Ritonavir

Hydroxychloroquine

Standard care

Standard care

Standard care

Hydroxychloroquine

HCQ+LPV/r

HCQ+LPV/r

RCT Patients with suspected or confirmed COVID-19 (critical) admitted to a multiple centers in Australia, Canada, France, Germany, Ireland, Netherlands, New Zealand, Portugal, Saudi Arabia, UK, and USA N=726
Some concerns
Details

Full description

NCT04403100
TOGETHER
Reis G, JAMA, 2021
Full text
Commentary
Commentary
Public/non profit

Lopinavir-Ritonavir

Hydroxychloroquine

Lopinavir-Ritonavir

Placebo

Placebo

Hydroxychloroquine

RCT Outpatients with confirmed COVID-19 (mild) treated at local public health facilities in 10 cities in Brazil N=685
Some concerns
Details

Full description

NCT04315948
DisCoVeRy
Ader F, medRxiv, 2022
Full text
Full text
Commentary
Commentary
Commentary
Mixed

Lopinavir-Ritonavir

LPV/r+IFN beta-1a

Hydroxychloroquine

Lopinavir-Ritonavir

Lopinavir-Ritonavir

LPV/r+IFN beta-1a

Standard care

Standard care

Standard care

LPV/r+IFN beta-1a

Hydroxychloroquine

Hydroxychloroquine

RCT Patients with confirmed COVID-19 (mild-critical) admitted to 32 centers in France and Luxembourg. N=603
Some concerns
Details

Full description

ISRCTN83971151; NCT04315948
SOLIDARITY (LPV/r)
Pan H, N Engl J Med, 2020
Full text
Full text
Commentary
Mixed

Lopinavir-Ritonavir

Standard care

RCT Patients with COVID-19 (mild-critical) admitted to 405 centers in 30 countries. N=2791
Low
Details

Full description

NCT04381936
RECOVERY (LPV/r)
Horby P, Lancet, 2020
Full text
Commentary
Mixed

Lopinavir-Ritonavir

Standard care

RCT Patients with suspected or confirmed COVID-19 (mild-critical) admitted to 163 centers in the UK N=5040
Some concerns
Details

Full description

ChiCTR2000029308
Cao B, N Engl J Med, 2020
Full text
Commentary
Commentary
Mixed

Lopinavir-Ritonavir

Standard care

RCT Patients with confirmed COVID-19 (severe) admitted to a single center in China. N=199
Some concerns
Details

Full description

NCT04252885
Yueping L, CellPress, 2020
Full text
Commentary
Public/non profit

Lopinavir-Ritonavir

Umifenovir

Lopinavir-Ritonavir

Standard care

Standard care

Umifenovir

RCT Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in China. N=86
Some concerns
Details

Full description